382 results on '"Gockerman, Jon P."'
Search Results
102. Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
103. High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: A case series
104. Alemtuzumab in Relapsed or Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia
105. Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.
106. Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy.
107. Fine-needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intra-abdominal lymphomas
108. Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells
109. Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis
110. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
111. High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
112. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy
113. Iodine-131 -Metaiodobenzylguanidine Uptake in Metastatic Carcinoid Tumor to the Orbit.
114. The Abnormal Surface Characteristics of the Red Blood Cell Membrane in Congenital Dyserythropoietic Anaemia Type II (HEMPAS).
115. Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein.
116. The lipids of the erythrocyte in paroxysmal nocturnal hemoglobinuria.
117. ALTERED IMMUNOLOGIC RECONSTITUTION AFTER STANDARD-DOSE CHEMOTHERAPY OR HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW SUPPORT.
118. Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification
119. Oligoclonal TRBV gene usage among CD8+ T cells in monoclonal B lymphocytosis and CLL.
120. Oral Manifestations of the Chronic Graft- v-Host Reaction
121. Drug-Induced Interstitial Lung Diseases
122. ALTERED IMMUNOLOGIC RECONSTITUTION AFTER STANDARDDOSE CHEMOTHERAPY OR HIGHDOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW SUPPORT
123. Purification and Characterization of Papain-Solubilized HLA Antigens From Human Platelets
124. Isoantibody Specificity in Post-transfusion Purpura
125. Oral candidiasis in cancer patients.
126. Hereditary Thrombotic Thrombocytopenic Purpura: Microangiopathic Hemolytic Anemia, Thrombocytopenia, and Renal Insufficiency Occurring in Consecutive Generations.
127. RBC Transfusions in Paroxysmal Nocturnal Hemoglobinuria
128. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia
129. Vitamin A in liposomes. Inhibition of complement binding and alteration of membrane structure
130. Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature
131. Cytomegalovirus glomerulopathy: A controversial lesion
132. Clinicopathologic and Cytogenic Features of CD34 (My 10)-Positive Acute Nonlymphocytic Leukemia
133. Immune deficiency and expanded population of granular lymphocytes after bone marrow transplantation
134. Measurement of the Third Component of Complement Bound to Red Blood Cells in Patients with the Cold Agglutinin Syndrome
135. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC
136. Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
137. P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC
138. Renal Lymphoma in an Azotemic Patient: Usefulness of Magnetic Resonance Imaging.
139. Aplastic anaemia as an autoimmune complication of thymoma.
140. Predictors of Survival in CLL: Multivariate Analyses Reveal Significant Correlation with IgVHGene Mutation Status, Clinical Stage, and Cellular CD38 (but Not Zap-70) Expression.
141. Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
142. Outcomes of Patients Who Undergo Aggressive Induction Therapy for Secondary Acute Myeloid Leukemia.
143. CLL cell apoptosis induced by nitric oxide synthase inhibitors: Correlation with lipid solubility and NOS1 dissociation constant
144. Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels
145. P102. Induction of chronic lymphocytic leukemia (CLL) apoptosis by nitric oxide synthase (NOS) inhibitors: Drug efficacy correlates with lipid solubility and NOS1 dissociation constant
146. NCCN Clinical Practice Guidelines Occult primary.
147. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
148. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
149. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
150. Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.